Clean Yield Group trimmed its stake in Quest Diagnostics Inc (NYSE:DGX) by 11.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,845 shares of the medical research company’s stock after selling 600 shares during the period. Clean Yield Group’s holdings in Quest Diagnostics were worth $517,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors also recently added to or reduced their stakes in DGX. IFP Advisors Inc boosted its position in Quest Diagnostics by 92.6% in the 4th quarter. IFP Advisors Inc now owns 262 shares of the medical research company’s stock valued at $27,000 after buying an additional 126 shares during the period. NuWave Investment Management LLC boosted its position in Quest Diagnostics by 108.4% in the 3rd quarter. NuWave Investment Management LLC now owns 346 shares of the medical research company’s stock valued at $36,000 after buying an additional 180 shares during the period. Quest Capital Management Inc. ADV purchased a new stake in Quest Diagnostics in the 3rd quarter valued at about $42,000. Webster Bank N. A. purchased a new stake in Quest Diagnostics in the 3rd quarter valued at about $54,000. Finally, Doyle Wealth Management purchased a new stake in Quest Diagnostics in the 2nd quarter valued at about $59,000. 88.08% of the stock is owned by institutional investors.
Shares of DGX opened at $107.06 on Friday. The company has a 50 day moving average price of $106.32 and a 200-day moving average price of $103.74. Quest Diagnostics Inc has a fifty-two week low of $82.59 and a fifty-two week high of $108.95. The stock has a market capitalization of $14.42 billion, a PE ratio of 16.97, a PEG ratio of 2.09 and a beta of 0.85. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.83 and a current ratio of 0.88.
Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings results on Tuesday, October 22nd. The medical research company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.71 by $0.05. Quest Diagnostics had a net margin of 9.58% and a return on equity of 15.32%. The firm had revenue of $1.96 billion during the quarter, compared to analysts’ expectations of $1.94 billion. During the same quarter in the prior year, the company earned $1.68 EPS. The company’s revenue was up 3.5% compared to the same quarter last year. Equities research analysts forecast that Quest Diagnostics Inc will post 6.49 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 29th. Investors of record on Tuesday, January 14th will be paid a dividend of $0.53 per share. The ex-dividend date is Monday, January 13th. This represents a $2.12 annualized dividend and a dividend yield of 1.98%. Quest Diagnostics’s dividend payout ratio (DPR) is presently 33.60%.
Several equities research analysts have issued reports on DGX shares. Wells Fargo & Co started coverage on shares of Quest Diagnostics in a research report on Tuesday, January 7th. They issued an “underweight” rating and a $100.00 price objective for the company. Canaccord Genuity reaffirmed a “buy” rating and issued a $113.00 price target on shares of Quest Diagnostics in a research report on Wednesday, October 23rd. Barclays cut shares of Quest Diagnostics from an “overweight” rating to an “equal weight” rating and set a $106.00 price target for the company. in a research report on Tuesday, January 7th. Bank of America cut shares of Quest Diagnostics from a “neutral” rating to an “underperform” rating in a research report on Friday, January 3rd. Finally, UBS Group lowered their price target on shares of Quest Diagnostics from $103.00 to $102.00 and set a “neutral” rating for the company in a research report on Monday, October 21st. Five equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the stock. Quest Diagnostics presently has an average rating of “Hold” and an average price target of $106.07.
In related news, SVP Michael E. Prevoznik sold 44,556 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $107.43, for a total transaction of $4,786,651.08. Following the completion of the transaction, the senior vice president now owns 51,321 shares in the company, valued at approximately $5,513,415.03. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Gail R. Wilensky sold 8,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $107.17, for a total transaction of $857,360.00. Following the transaction, the director now owns 22,951 shares of the company’s stock, valued at approximately $2,459,658.67. The disclosure for this sale can be found here. Insiders own 1.86% of the company’s stock.
Quest Diagnostics Company Profile
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Featured Article: How To Calculate Debt-to-Equity Ratio
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.